Predictors of response to daclatasvir in addition to sofosbuvir in hepatitis C virus-infected patients with stage 4 and 5 chronic kidney disease and patients on maintenance hemodialysis
Abstract Background The FDA authorized the use of sofosbuvir-based therapy in persons with chronic kidney disease (CKD) stages 4 and 5 and in those on maintenance hemodialysis (HD). It has been known that treatment efficacy might be affected by virus- and host-related parameters. The aim of this stu...
Saved in:
| Main Authors: | , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
SpringerOpen
2025-01-01
|
| Series: | The Egyptian Journal of Internal Medicine |
| Subjects: | |
| Online Access: | https://doi.org/10.1186/s43162-024-00393-7 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|